Milatuzumab doxorubicin

N/A

Report date: 2024/02/05 13:52:43

Base Information

Drug NameMilatuzumab doxorubicin

Drug Alias NameMilatuzumab-DOXIMMU-110hLL1-DOXhCD74-DOXCD-74-DOX

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Hydrazone linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Doxorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitorsAnti-CD74

TargetsTopoisomerase IIDNAHLA-DR antigens-associated invariant chain

Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGilead Sciences Inc

Active IndicationsN/A

Inactive IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A